News
The day at a glance · 3 min read
Mood · Cautious
+15
Sentiment, −100 to +100
PFE Close
$24.48+1.28%
Big Pharma & Drug Pricing Policy
PFE Yield
7%
Big Pharma & Drug Pricing Policy
Blood Glucose Market 2025
$16.8B
Medical Devices & Diagnostics
Key driverDrug pricing policy developments and diabetes diagnostics innovation offset by managed care membership concerns
Daily briefHealthcare· Money365.Market AI ·

Drug Pricing Policy, Diagnostics Advances Dominate

Trump pricing deals reshape Big Pharma outlook; Dexcom wins Canadian approval for 15-day CGM; J&J, UNH earnings ahead

Big Pharma & Drug Pricing Policy

Neutral
PFEABTLLY
Pfizer ($PFE) closed at $24.48, up 1.28%, as investors weighed drug pricing developments and pipeline strength. The Trump administration's drug-pricing deals are reshaping the competitive landscape for $PFE, AbbVie, and Bristol Myers Squibb, with analysts noting that pipelines matter even more than pricing in determining long-term value.
Abbott Laboratories ($ABT) is down 23% this year, while $PFE offers a 7% yield, with both beating Q1 estimates amid sector-wide pricing pressure.
Eli Lilly ($LLY) passed Navellier's high-growth screen, demonstrating exceptional sales, earnings, and cash flow growth despite the evolving pricing environment.

Medical Devices & Diagnostics

Bullish

Blood Glucose Market 2026

$18.3B

Blood Glucose Market 2035

$39.4B+8.9% CAGR
DXCMABT
Dexcom ($DXCM) announced Health Canada has authorized the Dexcom G7 15 Day Continuous Glucose Monitoring System for people 18 years and older living with diabetes, extending wear time and continuity for Canadian adults. The global blood glucose monitoring system market was valued at approximately $16.8 billion in 2025 and is expected to reach $18.3 billion in 2026, growing to $39.4 billion by 2035 at a CAGR of 8.9%.
Abbott ($ABT) is positioned in this expanding diagnostics market alongside $DXCM and Insulet Corporation. Alamar Biosciences shares climbed 7.3% to a new 52-week high of $28.42 on Alzheimer's diagnostics momentum, while the S&P 500 gained 0.4%.

Managed Care & Earnings Preview

Neutral
UNHJNJ
UnitedHealth Group ($UNH) faces Q2 pressure from membership declines ahead of July 16 earnings, though medical cost management and long-term growth initiatives remain investor focus areas.
Johnson & Johnson ($JNJ) hit fresh all-time highs last week, with Q2 results scheduled for Wednesday, July 15, before the opening bell. The company maintains its Dividend King status with more than 60 consecutive years of payout increases, and is advancing chronic kidney disease therapies alongside AstraZeneca, Novartis, Bayer, and Amgen.

Biotech Pipeline & M&A

Bullish

Head & Neck Cancer Market CAGR

10.5%
JNJ
Madrigal Pharmaceuticals announced it received three new U.S. patents for its lead drug Rezdiffra, sparking retail trader buzz over M&A speculation and intellectual property protection for its liver disease therapy. The head and neck squamous cell carcinoma market is projected to grow at a CAGR of 10.5% during the forecast period, driven by rising incidence of head and neck cancers worldwide and the expected launch of emerging therapies including Amivantamab from Johnson & Johnson ($JNJ), BNT113 from BioNTech, and other novel immunotherapies. Opportunities in chronic kidney disease care include integrating cardio-renal strategies, aligning therapies with real-world evidence, and leveraging site-of-care economics.

Looking Ahead

Neutral
JNJUNH
Johnson & Johnson ($JNJ) reports Q2 earnings Wednesday morning, with investors watching for guidance on the MedTech segment and pharmaceutical pipeline updates.
UnitedHealth ($UNH) follows on July 16, with membership trends and medical cost ratios as key metrics. Analysts continue monitoring the impact of drug pricing negotiations on Big Pharma margins, particularly for companies facing patent cliffs alongside pricing pressure.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy